CA2728328C - Treatment of antibiotic-resistant bacteria infection - Google Patents

Treatment of antibiotic-resistant bacteria infection Download PDF

Info

Publication number
CA2728328C
CA2728328C CA2728328A CA2728328A CA2728328C CA 2728328 C CA2728328 C CA 2728328C CA 2728328 A CA2728328 A CA 2728328A CA 2728328 A CA2728328 A CA 2728328A CA 2728328 C CA2728328 C CA 2728328C
Authority
CA
Canada
Prior art keywords
compound
mrsa
resistant
bacteria
vancomycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2728328A
Other languages
English (en)
French (fr)
Other versions
CA2728328A1 (en
Inventor
Ming-Chu Hsu
Chi-Hsin Richard King
Shu-Jen Chen
Luke Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiGen Biotechnology Co Ltd
Original Assignee
TaiGen Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiGen Biotechnology Co Ltd filed Critical TaiGen Biotechnology Co Ltd
Publication of CA2728328A1 publication Critical patent/CA2728328A1/en
Application granted granted Critical
Publication of CA2728328C publication Critical patent/CA2728328C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2728328A 2008-07-01 2008-09-08 Treatment of antibiotic-resistant bacteria infection Active CA2728328C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7729308P 2008-07-01 2008-07-01
US61/077,293 2008-07-01
PCT/US2008/075549 WO2010002415A1 (en) 2008-07-01 2008-09-08 Treatment of antibiotic-resistant bacteria infection

Publications (2)

Publication Number Publication Date
CA2728328A1 CA2728328A1 (en) 2010-01-07
CA2728328C true CA2728328C (en) 2015-02-24

Family

ID=41464848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2728328A Active CA2728328C (en) 2008-07-01 2008-09-08 Treatment of antibiotic-resistant bacteria infection

Country Status (13)

Country Link
US (1) US8211909B2 (https=)
EP (1) EP2303271B1 (https=)
JP (1) JP2011526887A (https=)
KR (2) KR20110044168A (https=)
CN (1) CN101618038B (https=)
AU (1) AU2008358909B2 (https=)
CA (1) CA2728328C (https=)
EA (1) EA018653B1 (https=)
NZ (1) NZ588898A (https=)
TR (1) TR201820964T4 (https=)
TW (1) TWI375558B (https=)
WO (1) WO2010002415A1 (https=)
ZA (1) ZA201100616B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101392808B1 (ko) * 2011-12-30 2014-05-12 순천대학교 산학협력단 식물 추출물 또는 이의 분획물을 포함하는 항균용 조성물
CN103145615B (zh) * 2013-03-20 2015-07-29 浙江医药股份有限公司 一种奈诺沙星螯合物的后处理方法
KR101392810B1 (ko) * 2013-09-25 2014-05-12 순천대학교 산학협력단 된장풀 추출물 또는 이의 분획물을 포함하는 항균용 조성물
US9492374B2 (en) 2015-03-25 2016-11-15 Jose Rafael Salinas Andrade Composition and method for treatment of ulcers
CN105368825B (zh) * 2015-10-14 2019-09-10 华东医院 幽门螺杆菌抗生素耐药性分析试剂盒及耐药性检测方法
AU2018385789B2 (en) * 2017-12-11 2024-02-15 Denovamed Inc. 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1H-tetrazole for the topical treatment of bacterial infections
CN111979292B (zh) * 2020-07-27 2022-08-05 广东省微生物研究所（广东省微生物分析检测中心） 一种同时携带多重耐药基因cfr和lsa(E)的MRSA的用途
CN114437026A (zh) * 2021-10-26 2022-05-06 浙江医药股份有限公司新昌制药厂 一种低组合物杂质的苹果酸奈诺沙星原料药及其制备方法
CN118852222B (zh) * 2024-06-27 2025-09-05 南京桦冠生物技术有限公司 一种奈诺沙星中间体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US100800A (en) 1870-03-15 Improvement in riding attachments for plows
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
SK286420B6 (sk) * 1997-09-15 2008-09-05 The Procter & Gamble Company Zlúčenina so štruktúrou chinolónu, farmaceutický prostriedok s jej obsahom a jej použitie
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
US6348624B1 (en) 1998-01-09 2002-02-19 The Procter & Gamble Co. Process for making certain benzoic acid compounds
MXPA03005338A (es) 2000-12-14 2003-10-06 Procter & Gamble Etapa de ciclizacion en el procedimiento de elaboracion de quinolonas y naftiridinas.
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
US6803469B2 (en) 2002-08-05 2004-10-12 The Procter & Gamble Company Process for preparing quinolone antibiotic intermediates
WO2005026145A2 (en) 2003-09-12 2005-03-24 Warner-Lambert Company Llc Quinolone antibacterial agents
CA2647457C (en) 2006-03-28 2011-05-24 The Procter & Gamble Company A hydride reduction process for preparing quinolone intermediates
MX2008012488A (es) 2006-03-28 2008-10-10 Procter & Gamble Un proceso de acoplamiento para preparar intermedios de quinolona.
EP2001862B1 (en) 2006-03-28 2011-04-27 Warner Chilcott Company, LLC Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
US8658183B2 (en) * 2007-08-09 2014-02-25 Taigen Biotechnology Company, Ltd. Antimicrobial parenteral formulation
JP2011528354A (ja) * 2008-07-15 2011-11-17 タイゲン バイオテクノロジー カンパニー，リミテッド 抗生物質

Also Published As

Publication number Publication date
EP2303271A4 (en) 2012-01-25
TWI375558B (en) 2012-11-01
AU2008358909B2 (en) 2012-12-13
KR20110044168A (ko) 2011-04-28
ZA201100616B (en) 2011-10-26
NZ588898A (en) 2012-09-28
TR201820964T4 (tr) 2019-01-21
JP2011526887A (ja) 2011-10-20
HK1139049A1 (en) 2010-09-10
EP2303271B1 (en) 2018-11-07
EP2303271A1 (en) 2011-04-06
KR20150006080A (ko) 2015-01-15
CN101618038A (zh) 2010-01-06
US8211909B2 (en) 2012-07-03
CA2728328A1 (en) 2010-01-07
EA018653B1 (ru) 2013-09-30
EA201170121A1 (ru) 2011-06-30
WO2010002415A1 (en) 2010-01-07
TW201002322A (en) 2010-01-16
AU2008358909A1 (en) 2010-01-07
US20100004282A1 (en) 2010-01-07
CN101618038B (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
CA2728328C (en) Treatment of antibiotic-resistant bacteria infection
Brighty et al. The chemistry and biological profile of trovafloxacin.
CA2693041C (en) Antimicrobial parenteral formulation
US20120157492A1 (en) Antibiotic drug
AU2010245097B2 (en) Methods of treating bacterial infections using oritavancin
US10329262B2 (en) Quinazolinone antibiotics
US20100041697A1 (en) Pneumonia treatment
Meena et al. Moxifloxacin and its therapeutic uses in animals: An overview
TW202400146A (zh) 美羅培南與法硼巴坦的組合之用途
HK1139049B (en) Use of a compound for the preparation of a medicament in treatment of antibiotic-resistant bacteria infection
EP4342484A1 (en) Pharmaceutical composition comprising macrocosine compound and method for preparing macrocosine compound
KR20230085579A (ko) 항병원성 활성 및 바이오필름 형성 억제 효과를 나타내는 화합물의 신규한 용도
CN114786681A (zh) 齐多夫定和氟喹诺酮抗生素的组合
WO2005046674A2 (en) Antibacterial compositions
HK1139050B (en) Medicament for the treatment of pneumonia
HK1139132B (en) Pneumonia treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251023

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260420